English | 中文版 | 手机版 企业登录 | 个人登录 | 邮件订阅
厂商 仪器 试剂 服务 新闻 文章 视频 高级搜索
当前位置 > 首页 > 行业资讯 > 展会 > 国际干细胞盛会IrvineScientific与您相约洛杉矶
国际干细胞盛会IrvineScientific与您相约洛杉矶
点击次数:1513 发布日期:2019-6-21  来源:本站 本站原创,转载请注明出处

 

ISSCR成立于2002年,是一个专业致力于干细胞研究的非营利性跨国、跨学科科学组织,目前在全球60多个国家和地区拥有4,000多名成员。ISSCR旨在推动和促进与干细胞有关的信息和想法的交流与传播,推进干细胞研究和应用领域的专业和公共教育及干细胞科学家、医生间的全球协作,促进干细胞的基础研究和临床应用。ISSCR是世界最大的国际干细胞会议,每年的年会和国际研讨会都是干细胞领域的重大事项。

 

2019年ISSCR年会将汇集来自世界各地的干细胞研究领域学者及行业精英4000多人,一起讨论交流干细胞科学和再生医学的科研和临床应用进展。

 


届时,富士胶片(FUJIFILM)集团成员 - 全球领先的细胞培养基产品服务供应商FUJIFILM Irvine Scientific公司将携全线细胞治疗培养基产品(如下)以展台和演讲形式参与此次盛会,

 

- 新一代无血清、无动物源、化学成分限定的T细胞培养基

- 新一代无血清、无动物源、化学成分限定的NK细胞培养基

- 新一代无血清、无动物源、化学成分限定的DC培养基

新一代无血清、无异源组分的间充质干细胞培养基

- cGMP级别无血清、无蛋白、无DMSO的细胞冻存液

 


 

6月27日,FUJIFILM Irvine Scientific科学家Vanda博士会在Innovation Showcase专题板块做题为< UNDERSTANDING THE USE OF CANCER STEM CELLS IN CELL THERAPY >的技术报告,介绍公司在新一代无血清细胞治疗培养基开发的思路和进展。

 

Abstract

 

Cancer is a devastating disease and a large effort has been made to develop cancer therapies. Immunotherapy has been the focus of extensive research and recently two T cell based therapies have been made available in the market. Despite the promising results, advances in the understanding of cancer biology and drug testing will continue to be crucial. Cancer stem cells (CSC), or cancer initiating cells, have been identified as cells that lead to tumor initiation and therapy failures. They are usually refractory to the most commonly used cancer therapies and their ability to self-renew, tumor initiating ability and differentiation potential lead to disease recurrence. It is thus crucial to understand CSC cell biology and develop effective strategies that target these cells. As with most of the adult stem cell populations, CSC are typically present in small numbers and require expansion and 3D structure formation for effective in vitro studies and drug development. 

 

FUJIFILM Irvine Scientific has developed a serum-free, cGMP solution that allows the expansion and  formation of cancer initiating cell tumorspheres. By following a rational design media development and extensive know-how we have eliminated the need for serum in the culture process. Serum-free solutions  will allow for a standardization of results among different laboratories, and provide a consistent performance product. In this presentation we will introduce our PRIME XV ® Tumorsphere SFM. We will also introduce other PRIME XV solutions that target cancer drug discovery and immunotherapy.  

 

FUJIFILM Irvine Scientific

无血清细胞培养基产品目录

 

相关阅读

Irvine Scientific推出最新一代CHO细胞浓缩补料以支持高效生物制药工业生产

《工业无血清培养基开发策略和新一代解决方案》

无动物源、化学成分明确的T细胞培养基的开发

 

如果您对FUJIFILM Irvine Scientific的新一代细胞无血清细胞培养基产品有兴趣,或者希望申请样品,请发邮件至Biopharma@fujifilm.com,谢谢。

索取资料
相关公司:欧莞科技咨询(上海)有限公司
联系电话:13816964879
E-mail:Jeff.feng@fujifilm.com



网友评论 已有[0]人评论
用户名: 密码: 匿名 快速注册 忘记密码
评论只代表网友观点,不代表本站观点。 请输入验证码: 8795
Copyright(C) 1998-2019 生物器材网 电话:021-64166852;13621656896 E-mail:info@bio-equip.com